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Abstract  (200 words, max=200) 
Mitochondrial dynamics and quality control are crucial for neuronal survival and their 
perturbation is a major cause of neurodegeneration. m-AAA complex is an ATP-dependent 
metalloprotease located in the inner mitochondrial membrane and involved in protein quality 
control. Mutations in the m-AAA subunits AFG3L2 and paraplegin are associated with 
autosomal dominant spinocerebellar ataxia (SCA28) and autosomal recessive hereditary 
spastic paraplegia (SPG7), respectively. We report a novel m-AAA-associated phenotype 
characterized by early-onset optic atrophy with spastic ataxia and L-Dopa-responsive 
parkinsonism. The proband carried a de-novo AFG3L2 heterozygous mutation (p.R468C) 
along with a heterozygous maternally-inherited intragenic deletion of SPG7. Functional 
analysis in yeast demonstrated the pathogenic role of AFG3L2 p.R468C mutation shedding 
light on its pathogenic mechanism. Analysis of patient's fibroblasts showed an abnormal 
processing pattern of OPA1, a dynamin-related protein essential for mitochondrial fusion and 
responsible for most cases of hereditary optic atrophy. Consistently, assessment of 
mitochondrial morphology revealed a severe fragmentation of the mitochondrial network, not 
observed in SCA28 and SPG7 patients’ cells. This case suggests that coincidental mutations 
in both components of the mitochondrial m-AAA protease may result in a complex 
phenotype and reveals a crucial role for OPA1 processing in the pathogenesis of 
neurodegenerative disease caused by m-AAA defects. 
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1.  INTRODUCTION 
The mitochondrial matrix AAA metalloprotease (m-AAA) is an ATP-dependent proteolytic 
complex located in the inner mitochondrial membrane (IMM), where it carries out protein 
quality control by degrading non-assembled or damaged proteins of the IMM and participates 
in the processing and maturation of some mitochondrial proteins (Esser et al., 2002; Nolden 
et al., 2005; Koppen & Langer, 2007). In humans, m-AAA exists in two different subunit 
compositions: a heterocomplex composed of AFG3L2 and paraplegin and a homocomplex 
constituted of AFG3L2 only. Interestingly, mutations in AFG3L2 (MIM# 604581) cause an 
autosomal dominant form of spinocerebellar ataxia (SCA28, MIM# 610246) (Di Bella et al., 
2010), while loss-of-function mutations in SPG7 (encoding paraplegin, MIM# 602783) cause 
an autosomal recessive form of hereditary spastic paraplegia (SPG7, MIM# 607259) (Casari 
et al., 1998). Furthermore, homozygous hypomorphic AFG3L2 mutations have been 
associated with a complex autosomal recessive spastic ataxia syndrome (SPAX5, MIM# 
614487) (Pierson et al., 2011; Muona et al., 2015), while dominant mutations of SPG7 (Klebe 
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et al., 2012) and AFG3L2 (Charif et al., 2015) have been associated with nonsyndromic 
dominant optic atrophy (DOA). 
 We report here co-occurrence of a heterozygous de-novo AFG3L2 missense mutation 
(p.R468C) and a maternally-inherited heterozygous intragenic deletion of SPG7 in a patient 
with a complex ataxic and extrapyramidal phenotype with early-onset optic atrophy. 
Interestingly, the AFG3L2 p.R468C mutation was recently reported in a dominant family 
with optic atrophy and mild intellectual disability (Charif et al., 2015) and in a sporadic 
patient with isolated optic atrophy (Colavito et al., 2017). In neither case did the patients 
manifest ataxia, spasticity, or extrapyramidal involvement. Thus, the clinical and cellular 
studies described here suggest that co-occurrence of AFG3L2 and SPG7 mutations may result 
in a new complex phenotype not attributable to either of the two genes individually.   
2.  MATERIALS AND METHODS  
2.1  Patient and DNA samples 
All procedures involving human subjects were approved by the Institutional Review Board of 
the Fondazione IRCCS Istituto Neurologico ―Carlo Besta‖, Milan, Italy, in agreement with 
the Declaration of Helsinki. Each individual providing a biological sample signed written 
informed consent approved by the Institutional Review Board of the Foundation IRCCS 
Istituto Neurologico Carlo Besta, Milan, Italy, in agreement with the Declaration of Helsinki. 
Genomic DNA was prepared from peripheral-blood lymphocytes using standard procedures 
as previously described (Gellera et al., 2007).  
 Magri et al. -  
 
This article is protected by copyright. All rights reserved. 
 
5 
2.2  Genetic studies 
Mutation screening of AFG3L2, SPG7, and OPA1 (MIM# 605290) genes was performed by 
Sanger sequencing, while copy number variation of SPG7 was detected by MLPA (Multiplex 
Ligation-dependent Probe Amplification, MRC-Holland, Amsterdam, The Netherlands). 
Sequences of the oligonucleotide primers are available upon request. DNA mutation 
numbering system is based on cDNA sequence. Nucleotides are numbered so that the first 
nucleotide of the first in-frame ATG codon in the reference sequence is nucleotide +1. Amino 
acids are numbered so that methionine encoded by the first in-frame ATG codon in the 
reference sequence is Met1.  
Segregation study was performed using a ultra-deep (≥20,000X) sequencing of PCR 
amplicons. NGS library was prepared from PCR amplicons using Nextera XT DNA Library 
Preparation Kit (Illumina, Inc., San Diego, CA, USA) according to the manufacturer’s 
instructions and sequenced on a MiSeq sequencing apparatus (Illumina, Inc.) with high depth 
of coverage (>20,000-fold) for mosaicism detection.  
Paternity testing was performed using multiallelic variable number of tandem repeat 
(VNTR) polymorphisms 3’APOB-VNTR (Deka et al., 1992) and D11S533 (Eubanks et al., 
1991). 
Sequencing of 4,813 genes associated with known clinical phenotypes was performed 
using TruSight One sequencing panel kit (Illumina, Inc.; www.illumina.com/trusightone) on 
an Illumina MiSeq sequencer according to the manufacturer’s instructions. Data analysis was 
performed using: a) MiSeq Reporter software (Illumina, Inc.) for alignment and variant 
calling; b) VariantStudio software (Illumina, Inc.) for variant annotation; and c) CLC 
Genomics Workbench (CLCbio-Qiagen, Aarhus, Denmark) software for quality control and 
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coverage analysis. Filtering passing variants were classified and prioritized according to the 
ACMG Standards and Guidelines (Richards et al., 2015). Potentially pathogenic variants in 
genes associated with optic atrophy, dystonia, spastic paraplegia, ataxia, or Parkinson disease 
(Supp. Tables S1 and S2) were confirmed in the proband by Sanger sequencing and 
segregated in her parents by Illumina Nextera XT deep sequencing.  
2.3  AFG3L2 and paraplegin yeast expression plasmids 
Plasmids for heterologous expression of human AFG3L2 and paraplegin in yeast were 
generated as previously described (Di Bella et al., 2010). Mutations were introduced into the 
yeast construct pYC6/CTADH1-AFG3L2-V5/HIS using the QuikChange XL Site-Directed 
Mutagenesis Kit (Stratagene-Agilent, Cedar Creek, TX, USA). All AFG3L2 forms were C-
ter tagged with the V5 epitope (amino acid residues 95-108, GKPIPNPLLGLDST, of RNA 
polymerase alpha subunit of simian virus 5). Sequences of oligonucleotide primers used for 
site-directed mutagenesis are available upon request. Plasmid pYC2/CT-ADH1-AFG3L2-
myc carrying wild-type AFG3L2 was used to express AFG3L2
mut
/AFG3L2
wt
 complex  as 
previously described (Di Bella et al., 2010). Plasmid YCplac111ADH1-Yta10(1-63)-
paraplegin(59-795)-HA was used to express human paraplegin as previously described (Di 
Bella et al., 2010). 
2.4  Yeast strains and growth conditions 
All strains used in this study (Supp. Table S3) derived from W303 (K699, MATa ho ade2-1 
trp1-1 can1-100 leu2-3,12 his3-11,15 ura3 ssd1). A double-knockout yeast strain 
(yta10Δyta12Δ) was generated by deleting YTA10 and YTA12, the yeast orthologs of human 
AFG3L2 and paraplegin, respectively, using the one-step PCR system; the obtained strain 
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was transformed as previously described (Di Bella et al., 2010). Cells were grown at 28°C on 
YEP medium (1%-yeast extract, 2%-peptone, 2%-agar for plates) or selective medium 
supplemented with 2% (wt/vol) glucose according to standard procedures. Blasticidin-
resistant transformants were selected on YEP medium supplemented with 50 µg of blasticidin 
S per ml. For complementation experiments, equal amounts of five-fold serial dilutions of 
cells from exponentially grown cultures were spotted onto YEP plates containing 2% (wt/vol) 
glucose (YPD) or 2% (wt/vol) glycerol (YPG) and incubated at 28°C or 37°C, as indicated. 
For growth rate analysis, we precultured overnight yeast cells in selective medium 
supplemented with 2% (wt/vol) galactose and 0.1% (wt/vol) glucose and then cultured them 
in YEP medium supplemented with 2% (wt/vol) glycerol for 24 h, inoculated at a standard 
density of approximately 1 × 10
6
 cells/ml. We removed samples at 0h, 20h and 24h and 
determined cell density spectrophotometrically, expressed as OD600. For western blot 
analysis, yeast cells were cultured overnight in selective medium supplemented with 2% 
(wt/vol) galactose and 0.1% (wt/vol) glucose and normalized spectrophotometrically at 
OD600. 
2.5  Immunoblot analysis and antibodies 
For western blot analysis of yeast cells, trichloroacetic acid (TCA) protein extracts were 
prepared as described (Muzi-Falconi et al., 1993). Western blot analysis of COX subunits 
was performed on mitochondrial extracts. Protein extracts were separated by SDS-PAGE in 
10% or 15% acrylamide gels as indicated and transferred to a PVDF membrane (Immobilon 
LF, EMD Millipore/Fisher Scientific, Hampton, NH, USA). Filters were probed with 
antibodies  (Supp. Table S4) as indicated in the text and in the figure legends. Fluorescent 
blot was performed using Alexa Fluor
®
647-conjugated goat anti-rabbit IgG (H+L) antibody 
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and Alexa Fluor
®
488-conjugated goat anti-mouse IgG (H+L) antibody (Invitrogen Molecular 
Probes/Thermo Fisher Scientific Inc., Waltham, MA, USA). Fluorescence signals were 
acquired using the G:BOX iChemi apparatus (Syngene, Cambridge, UK); quantitation was 
performed using Gene Tools software (Syngene) on four independent western blots 
normalizing signals to the -actin loading control. For western blot analysis of patient-
derived lymphoblasts and fibroblasts, cell lysates from each line were electrophoresed on 
10%-15%-SDS-polyacrylamide gels and transferred to a nitrocellulose membrane 
(Amersham Biosciences/GE Healthcare Life Sciences, Little Chalfont, UK) by 
electroblotting. Filters were probed with indicated antibodies and developed by HRP-
conjugated secondary antibodies using a chemiluminescent substrate (ECL Prime, Amersham 
Biosciences). Signals were detected by G:BOX iChemi (Syngene). Quantitative analysis of 
OPA1 forms levels was performed using Gene Tools software (Syngene) on three 
independent immunoblots normalizing the signals to that of the alpha subunit of 
mitochondrial trifunctional protein (MTP) as the loading control. 
2.6  Assays of respiratory chain complexes activity 
For in vitro activity assay of Complex III, IV, and V and immunoblot analysis of cytochrome 
c oxidase (COX) subunits, yeast cells were grown at 28°C in YEP medium supplemented 
with 2% (wt/vol) galactose-0.1% (wt/vol) glucose. Yeast cell mitochondria were prepared by 
differential centrifugations. The resulting mitochondrial pellet was resuspended in 10-mM 
potassium phosphate buffer and freezed and thawed for three times. Protein concentration 
was determined by Bradford microplate microassay (Bio-Rad Laboratories, Hercules, CA, 
USA) with bovine serum albumin as the standard. Respiratory chain enzyme activities were 
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determined spectrophotometrically as previously described (Di Bella et al., 2010; Magri et 
al., 2010). Activity was expressed as nanomoles per minute per milligram of protein.  
2.7  Co-immunoprecipitation of AFG3L2 and paraplegin  
For immunoprecipitation experiments, yeast cells were precultured overnight in a selective 
medium and then grown in 100 ml of YPD medium until 1x 10
7
 cell/ml as previously 
described (Fracasso, 2010). Normalized cells were resuspended in PBS, 1 mM PMSF, 1 mM 
NaVa, 50 mM NaF supplemented with Complete Protease Inhibitor Cocktail (Hoffmann-La 
Roche, Basel, CH), and homogenized using the FastPrep® System (Qbiogene-MP 
Biomedicals). Homogenates were centrifuged and the resulting supernatants were incubated 
with anti-V5 antibodies (Invitrogen/Thermo Fisher Scientific Inc., Waltham, MA, USA). 
Antigen-antibody complexes were then incubated with Protein G Mag Sepharose (GE 
Healthcare Life Sciences, Little Chalfont, UK). Samples were eluted from beads and 
analysed by SDS-PAGE and immunoblotting. 
2.8  Patient-derived cell lines 
Epstein-Barr-virus-stabilized lymphoblastoid cell lines (LCL) from patients, their relatives 
and control subjects were established and cultured as previously described (Gellera et al., 
2007). Fibroblasts from patient and controls were grown in the DMEM-high glucose or -
galactose media as described previously (Wong et al., 1999).  
2.9  Analysis of mitochondrial morphology 
For analysis of mitochondrial morphology, fibroblasts were grown on coverslips inside a 
petri dish filled with the appropriate culture medium. When reached the desired confluence, 
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cells were incubated for 15 minutes with a medium containing 50-nM MitoTracker Red™ 
(Invitrogen Molecular Probes/Thermo Fisher Scientific Inc., Waltham, MA, USA). Stained 
cells were fixed using a 1:1 solution of 4% (w/v) saccharose and 4% (v/v) paraformaldeyde 
for 25 min at 37°C under weak agitation, and then in ice-cold methanol for 10 min at room 
temperature. Samples were analyzed with a Leica TCS NT confocal laser scanning 
microscope (Leica Lasertecknik GmbH, Heidelberg, Germany) equipped with a 75 mW 
Kripton/Argon mixed gas laser (Fig. 4B) or a Nikon Eclipse T1 fluorescent microscope with 
a oil objective (Supp. Fig. S9). 
For quantitative analysis of mitochondrial network morphology, acquired images of 
mitochondria were analyzed using NIH-developed Image J software (Wayne Rasband, NIH, 
Bethesda, MD, USA). Raw images were first enhanced by 2D deconvolution (Iterative 
Deconvolve 3D by Robert Dougherty, OptiNav, Inc., Bellevue, WA, USA) and then 
converted into binary (black and white) images. Mitochondrial particles were analyzed 
determining, for each object, several parameters such as area (Am), perimeter (Pm), maximal 
and minimal radius. We used Aspect Ratio (AR) and Formfactor (F) as quantitative 
descriptors of mitochondrial morphology. Aspect Ratio is the ratio between the major and 
minor axis of the ellipse equivalent to the mitochondrion and reports changes in length, 
whereas Formfactor (defined as [Pm2]/[4πAm]) allows to quantify the degree of branching 
(Koopman et al., 2006). Both parameters are independent from image magnification and have 
a minimal value of 1, corresponding to a circular mitochondrion. Higher values of AR and F 
correspond to longer and more branching mitochondria, respectively. The results are shown 
in the bar graphs in Fig. 4C, which represent average AR and F values calculated on at least 
four randomly selected cells cultured in glucose- or galactose-containing medium as 
indicated. 
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2.10 Gene expression analysis 
Total RNA was isolated from fibroblast cell lines derived from the affected patient and 4 
controls with Maxwell® 16 LEV simplyRNA Cell Kit, according to the manufacturer’s 
instructions (Promega Corporation, WI, USA). The quality and quantity of RNA were 
determined with a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific Inc., 
Waltham, MA, USA). One microgram of total RNA was reverse-transcribed using the 
SuperScript® VILO™ cDNA Synthesis Kit according to the manufacturer’s instructions 
(Thermo Fisher Scientific Inc., Waltham, MA USA). 
Gene expression analysis was performed by TaqMan real-time PCR (RT-PCR) using 
the following TaqMan® Assays (Thermo Fisher Scientific Inc., Waltham, MA, USA): 
OMA1 (Hs00377028_m1), OPA1 (Hs01047013_m1), GAPDH (Hs02758991_g1). 
Expression levels of OMA1 (MIM# 617081), OPA1, and GAPDH were determined using the 
Applied Biosystem Real Time-PCR 7300 system (Thermo Fisher Scientific Inc., MA, USA) 
following the manufacturer’s instructions. Real-time PCR reaction was carried out in a final 
volume of 20 μl using 10 μl TaqMan® Fast Advanced Master Mix, 1-μl TaqMan® Gene 
Expression Assays and 1 μl cDNA sample with a pre-incubation step at 50°C for 2 minutes 
and at 95°C for 20 seconds, followed by 40 cycles at 95°C for 3 seconds, 60°C for 30 
seconds. RT-PCR reactions were run in duplicate in each assay. The expression levels of 
OMA1 and OPA1, first normalized to the expression levels of the housekeeping gene 
GAPDH, were further normalized for both patient and controls to the expression levels of a 
control individual used as calibrator. The experiments were performed in triplicate. 
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3  RESULTS 
3.1  Case report 
The proband is a 25-year-old woman with negative family history. She has 
nonconsanguineous healthy parents and two unaffected twin brothers (Fig. 1A). The disease 
presented at the age of 5 years with severe visual impairment (bilateral 1/20 visual acuity) 
and signs of primary optic atrophy: reduction of optic disc size with mild diffuse pallor, 
wedge-shaped area of excavation of the temporal sector, normal retinal blood vessels. At the 
age of 6 years, the patient manifested a slowly progressive motor impairment characterized 
by bradykinesia, internal rotation of right foot, and gait and balance instability. At 10 years, 
brain magnetic resonance imaging (MRI), visual evoked potentials, electroretinogram, nerve 
conduction studies, motor and sensory evoked potentials, and electroencephalogram (EEG) 
were normal. Neuropsychological studies showed mild cognitive impairment (WISC-R 
IQ=62) with relative preservation of verbal abilities (V=76, P=50). Since 12 years, she also 
exhibited spastic paraparesis with mild ataxia, scanning speech and mild drooling. At 14 
years of age, L-dopa treatment (levodopa+carbidopa, 375+37.5 mg/die) was started, with 
significant improvement in gait function and global motility, but no effect on visual 
impairment. At 22 years of age, single photon emission computed tomography 
(SPECT)/dopamine transporter (DaT) scan showed marked bilateral dopaminergic defect in 
the striatum (Fig. 1B). Analysis of muscle biopsy showed normal muscle morphology, a mild 
reduction of complex I activity (10 nmol/min per mg protein; n.v., 13-24), and normal levels 
of Coenzyme Q10 and respiratory chain complexes II-V. At the age of 22 years, she 
experienced motor fluctuations characterized by ―wearing-off‖ with lower limb painful 
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dystonia and peak-dose dyskinesias with facial grimaces and cervical dystonic movements. 
At last examination (25 years), she had spastic-ataxia combined with rigid akinetic 
parkinsonism with right side prevalence (UPDRS motor score: 5/108 in ―on‖ state, 25/108 in 
―off‖ state). She exhibited good control of motor fluctuations after introduction of 4 mg/die 
rotigotine in association with levodopa+carbidopa (125+12.5 mg t.i.d.). Remarkably, brain 
MRI was still normal (Supp. Fig. S1). Optical coherent tomography (OCT) showed marked 
bilateral thinning of retinal fiber layer (RNFL) and ganglion cell layer (GCL) (Supp. Fig. S2). 
Cognitive evaluation (WISC-IV) confirmed discrepancy between verbal (VCI=73) and visual 
perceptual and speed processing skills (PRI=48, PSI=53), with mild working memory deficit 
(WMI=63). 
3.2  Genetic analysis 
Molecular screening for mitochondrial DNA Leber’s hereditary optic neuropathy (LHON, 
MIM# 535000) mutations (m.3460G>A, m.11778G>A, m.14459G>A, and m.14484T>C), 
and mutations in the OPA1 (MIM# 165500) (sequence and MLPA analysis) and GCH1 
(DYT5, MIM# 128230) genes resulted negative for pathogenic or likely pathogenic variants, 
while molecular analysis of AFG3L2 revealed a previously reported (Charif et al., 2015) 
heterozygous missense variant p.R468C (NM_006796.2:c.1402C>T, submitted to ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/)) (Fig. 1A) in the highly conserved SRH region of the 
ATPase domain. Both parents and the twin brothers were negative for the mutation and 
mosaicism was excluded by deep sequencing (>20,000X) analysis of parents’ DNA (Supp. 
Fig. S3C), thus indicating the de-novo nature of the p.R468C mutation in this family. Because 
of its functional and genetic interaction with AFG3L2, we screened SPG7 for mutations and 
identified a novel heterozygous deletion spanning exons 4 to 6 
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(NM_003119.3:c.(376+1_377-1)_(861+1_862-1)del, submitted to ClinVar) and predicted to 
cause premature termination of protein translation (p.Glu127SerfsTer2). The patient’s mother 
and the twin brothers, who carried only the SPG7 deletion, were completely unaffected, 
consistently with the recessive nature of SPG7 disease (Fig. 1A). Clinical exome analysis 
using Illumina TruSight One sequencing panel excluded the presence of pathogenic or likely 
pathogenic variants in other disease genes associated with optic atrophy, dystonia, spastic 
paraplegia, ataxia, or Parkinson disease (Supp. Tables S1 and S2). Finally, Southern blot 
analysis showed normal amount of normal-sized mtDNA with no evidence of deletions. 
3.3  Functional analysis of AFG3L2 p.R468C variant in yeast  
The functional consequences of AFG3L2 p.R468C variant were assessed using the yeast 
model we previously described (Di Bella et al., 2010). Human AFG3L2 protein carrying the 
p.R468C variant or two reference SCA28 pathogenic mutations (p.E691K, paraplegin-
nonresponsive, and p.S674L, paraplegin-responsive (Di Bella et al., 2010)) was expressed in 
a m-AAA–defective strain (yta10∆yta12∆ double-knockout strain) with and without 
paraplegin. Yeast cells lacking the endogenous m-AAA protease exhibit a respiratory defect 
(OXPHOS phenotype) which is complemented by wild-type AFG3L2 (AFG3L2
WT
) but not 
by AFG3L2
R468C
, indicating that this substitution is deleterious for homocomplex function 
(Fig. 2A). yta10∆yta12∆ cells carrying AFG3L2R468C/paraplegin also show an OXPHOS 
phenotype, indicating that the p.R468C mutation is not rescued by paraplegin (Fig. 2B). 
Furthermore, co-expression of AFG3L2
WT
 in cells carrying AFG3L2
R468C
 resulted in a very 
limited recovery of respiration (Supp. Fig. S4A) and in a persistent deficiency of both 
proteolytic and dislocase (ATPase) activities (Supp. Fig. S4B and C, respectively). 
Altogether, these experiments demonstrate the pathogenicity of the p.R468C variant and 
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suggest that it functionally inactivates both homo- and heterocomplex likely via a dominant-
negative mechanism (Veitia et al., 2018).  
 Enzyme activity assay of respiratory chain complexes III, IV, and V in AFG3L2
R468C
 
cells showed a reduction of >80% as compared to AFG3L2
WT
 (Fig. 2C). Notably, in 
comparison with the SCA28 mutations, the p.R468C is associated with a more severe 
cytochrome c oxidase (Cox) reduction (>90%) that persisted unchanged upon coexpression of 
paraplegin, consistent with the dominant effect of this mutation. Immunoblot protein level 
quantitation showed a severe reduction of both mitochondria-encoded Cox subunits (Cox1p, 
Cox2p, and Cox3p) and nucleus-encoded subunit Cox4p indicating a general downregulation 
of the whole enzyme (Supp. Fig. S5). 
 We also evaluated residual activity of human mutated m-AAA complexes, measuring 
the processing of the two known substrates of yeast m-AAA: the ROS-scavenger protein 
Ccp1 (Esser et al., 2002) and the ribosomal subunit MrpL32 (Nolden et al., 2005). In 
particular, the conversion of MrpL32 from precursor to mature form is an indicator of the 
overall proteolytic competence, while the maturation of Ccp1 indicates the ATP-dependent 
capacity of m-AAA complex to dislocate proteins from the IMM (dislocase activity) (Tatsuta 
et al., 2007; Bonn et al., 2011). Quantitation of protein precursor and mature levels showed 
that in yeast strains harbouring AFG3L2
R468C
, both alone or with paraplegin, approx. 90% of 
MrpL32 and Ccp1 accumulate as precursor (Fig. 3A-B), indicating that the p.R468C 
mutation disrupts both proteolytic and ATPase (dislocase) activity.  
 Remarkably, the severity of the AFG3L2 p.R468C mutation is also demonstrated by 
the impairment of its own maturation that physiologically occurs by autocatalytic processing 
(Koppen et al., 2009). We performed immunoblot analysis of strains expressing 
homocomplex carrying the disease-causing mutation p.R468C, the reference SCA28 
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mutations p.E691K and p.S674L (Di Bella et al., 2010), and the proteolytically inactive 
mutant p.E575Q (Koppen et al., 2009) (Fig. 3C). This latter mutant accumulates as a larger 
form (p, precursor) (Fig. 3C and Supp. Fig. S6A, lane 6), indicating that human AFG3L2 
undergoes autocatalytic processing as do the homolog mouse subunits Afg3l2 and Afg3l1 
(Koppen et al., 2009). Unlike the SCA28 mutants, AFG3L2
R468C
 accumulates also as 
precursor protein (Fig. 3C and Supp. Fig. S6A, lane 3), indicating that this mutation impairs 
AFG3L2 maturation. Notably, in strain expressing AFG3L2
R468C
 and paraplegin, both 
proteins are almost completely unprocessed (Fig. 3D and Supp. Fig. S6B, lane 3), indicating 
a more severe impairment of the heterocomplex than the homocomplex. These results may 
reflect the different functional organization of the homo- and heterocomplex and the specific 
role of arginine 468 in intersubunit communication acting as a sensor of ATP in the 
neighbour subunit (Ogura et al., 2004). Coordinated ATP hydrolysis within the AAA ring of 
m-AAA proteases has been proposed to increase the efficiency of the proteolytic machine 
(Augustin et al., 2009), likely by inducing conformational changes necessary for protease 
functioning (Suno et al., 2006). It is conceivable that the dynamic motion of the subunits may 
differ between the homo- and heterocomplex, making the latter more vulnerable to the 
presence of a mutation in the crucial ATP sensor 468 residue. 
 To investigate the ability of AFG3L2
R468C
 to assemble in a heterocomplex, we 
performed co-immunoprecipitation in strains co-expressing paraplegin and AFG3L2
WT
 or 
AFG3L2
R468C
 (Supp. Fig. S7), which showed that AFG3L2
R468C
 is able to interact with 
paraplegin in its precursor form (lane 6). 
 Altogether, co-expression studies, substrate processing experiments, and co-
immunoprecipitation results demonstrate that AFG3L2
R468C
 mutant can assemble into both 
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homomeric (AFG3L2/AFG3L2) and heteromeric (AFG3L2/paraplegin) complexes which are 
substantially inactive. 
3.4  Functional analysis in patient’s cells  
To investigate the effect of m-AAA impairment on human cellular phenotype, we studied 
fibroblasts and lymphoblastoid cell lines (LCL) derived from the patient and controls. First, 
immunoquantitation in the patient’s cells showed normal levels of AFG3L2 but reduced 
levels of paraplegin, consistent with heterozygosity for the SPG7 null mutation (Supp Fig. 
S8A). We then analysed the processing pattern of MRPL32 and OPA1, a dynamin-related 
protein crucial for mitochondrial dynamics and cristae morphogenesis, and responsible for 
most cases of dominant optic atrophy (MacVicar & Langer, 2016). Although both MRPL32 
and m-AAA are highly conserved in eukaryotes, their interaction is not clearly demonstrated 
in mammals (Nolden et al., 2005; Maltecca et al., 2008). As previously observed in SCA28 
patients’ cells (Di Bella et al., 2010), immunoblot analysis revealed normal processing of 
MRPL32 in patient’s fibroblasts cultured in both glucose and galactose (Supp. Fig. S8B). On 
the contrary, unlike what observed in SCA28 patients’ cells (Di Bella et al., 2010), OPA1 
presented an abnormal processing pattern (Fig. 4A). In particular, we observed a reduction of 
the long form L2 and the short form S2, and an accumulation of the S3 form. The same 
OPA1 pattern alteration was observed also in patient’s LCLs (Supp. Fig. S8A). 
Since under various stress conditions (loss of membrane potential, heat stress, 
reduction of ATP level, Bax/Bak aggregation, and other  mitochondrial stress conditions) the 
cleavage of OPA1 long forms is enhanced by the overactivation of OMA1, an inducible 
ATP-independent metalloprotease of the inner mitochondrial membrane (Quirós et al., 2012; 
Baker et al., 2014), we investigated whether an increase in OMA1 mRNA could be 
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implicated in the aberrant processing pattern of OPA1 observed in the patient’s cells (Supp. 
Fig. S10). We did not detect any statistically significant difference between OMA1 mRNA 
levels in patient’s and controls’ cells, which indicates that OMA1 increased activity, if any, is 
not mediated by transcriptional activation. 
Since a balance of short and long OPA1 forms is required for mitochondrial fusion 
activity in mammals (Song et al., 2007), we investigated the morphology of the mitochondrial 
network. Analysis by confocal microscopy revealed a significant fragmentation in patient’s 
fibroblasts as compared to control cells (Fig. 4B-C). Consistently, analysis of aspect ratio and 
formfactor (Koopman et al., 2006), which describe mitochondrial shape (length) and 
branching, respectively, showed significantly lower values in patient’s cells than in control 
cells (Fig. 4C). However, despite this mitochondrial fragmentation, oxygen consumption rate 
(OCR, determined using Seahorse Bioscience XF Cell Mito Stress Test) was similar in 
patient’s and controls’ fibroblasts (data not shown). Notably, this is consistent with the recent 
observation that energetic competence of the cell may be independent of mitochondrial 
network morphology (Del Dotto et al., 2017). 
 
4  DISCUSSION 
In the present study, we describe for the first time a patient carrying heterozygous mutations 
in the AFG3L2 and SPG7 genes that encode the subunits of the mitochondrial m-AAA 
protease: AFG3L2:p.R468C (de novo) and SPG7:p.Glu127SerfsTer2 (maternally-inherited). 
This genotype is associated with a severe complex phenotype characterized by early-onset 
optic atrophy, L-dopa-responsive syndromic parkinsonism with abnormal dopaminergic 
uptake in the basal ganglia on SPECT/DaTscan (Fig. 1B), spastic ataxia, and mild cognitive 
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impairment. An extensive sequence analysis of the known genes causing optic atrophy, 
Parkinson disease, and hereditary dystonia allowed to exclude other molecular causes for the 
observed phenotype. Interestingly, the AFG3L2 mutation p.R468C was recently described in 
a family with dominant optic atrophy and mild intellectual disability without any sign of 
ataxia, spasticity or extrapyramidal involvement (Charif et al., 2015) and in a sporadic patient 
with isolated optic atrophy (Colavito et al., 2017). While it was dominantly inherited in the 
first family, its transmission pattern could not be established in the second case. Interestingly, 
the de-novo nature of the mutation in our patient (Fig. 1A and Supp. Fig. S3) clearly indicates 
that AFG3L2 NM_006796.2:c.1402C is a mutational hotspot. 
The phenotype-genotype comparison between our AFG3L2/SPG7 patient and the 
patients with AFG3L2 p.R468C only (Charif et al., 2015; Colavito et al., 2017) suggests that 
the early-onset optic atrophy phenotype is due to this particular AFG3L2 mutation, whose 
effects are greatly aggravated in our patient by the concurrent defect of paraplegin. Unlike 
AFG3L2 mutations causing SCA28, which predominantly affect the proteolytic domain 
(Cagnoli et al., 2010; Di Bella et al., 2010), the p.R468C mutation involves a highly 
conserved arginine of the SRH region of the ATPase domain. The corresponding arginine of 
various AAA/AAA+ ATPases is essential for ATP hydrolysis because it acts as a sensor for 
the presence of ATP in the neighbour subunit interacting with the ATP γ-phosphate in the 
ATP-binding pocket of the adjacent subunit (Ogura et al., 2004). Thus, this residue represents 
the arginine finger which contributes to the coupling of the free energy of ATP hydrolysis to 
the conformational changes necessary to drive the translocation of a substrate polypeptide to 
the protease catalytic sites (Suno et al., 2006). Consistently, functional analysis in our yeast 
model demonstrated that p.R468C completely abolished both the ATPase-dependent 
dislocase activity, essential for the processing of membrane proteins (Fig. 3B), and the 
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proteolytic competence (Fig. 3A). Interestingly, we demonstrated that in yeast AFG3L2
R468C
 
retains the ability to assemble in complexes (Supp. Fig. S7) but is unable to support its 
autoprocessing and the proteolytic activation of paraplegin (Fig. 3C and D), which would 
indicate that the complex is inactive. By contrast, the SCA28 mutations (p.E691K and 
p.S674L (Di Bella et al., 2010)), that affect the proteolytic domain, not only modestly alter 
the ATP-dependent dislocase activity (these AFG3L2 mutants are able to process Ccp1 
almost as AFG3L2
WT
 does (Fig. 3B)), but also show a residual proteolytic activity (Fig. 3A, 
C, and D), which would indicate the formation of partially active complexes. The peculiar 
molecular pathomechanism of the AFG3L2
p.R468C
 mutation may therefore account for the 
different patient phenotypes (i.e., SCA28 vs. DOA)..  
Remarkably, our proband exhibits a complex phenotype that is very likely caused by 
the synergistic effect of a dominant-negative AFG3L2 mutation and the reduced levels of 
paraplegin due to a loss-of-function SPG7 mutation. The genetic interaction between 
AFG3L2 and SPG7 was demonstrated in mice, where the double mutants Spg7
-/-
Afg3l2
Emv66
/
+
 
show an early-onset severe neurological phenotype that represents an acceleration and 
worsening of the phenotype observed in single mutants (Martinelli et al., 2009). 
Haploinsufficient Afg3l2
Emv66
/
+
 mice appear normal at birth and do not show a remarkable 
phenotype up to 4 months of age when they develop a slowly progressive motor coordination 
deficit (Maltecca et al., 2009). By contrast, crossing these mice with paraplegin-deficient 
mice (Spg7
-/-
Afg3l2
Emv66
/
+
 double mutants) resulted in a severe neurological phenotype 
manifesting at 6 weeks of age, characterized by reduced cage activity, loss of balance, and 
frank uncoordinated gait with dystonic movements of the head by 9 weeks of age. Later, they 
lost significant weight, became cachexic, and eventually died within the 4th month of life 
(Martinelli et al., 2009). Therefore, these mice displayed an acceleration of the features of 
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paraplegin-deficient mice (Ferreirinha et al., 2004), showing axonal degeneration in the 
spinal cord much earlier (13 weeks vs. 8 months) than in the sole absence of Spg7. 
Altogether, these findings suggest that neurons are very sensitive to the global levels and the 
subunit composition of m-AAA proteases and lend support to the hypothesis that digenic 
inheritance of AFG3L2 and SPG7 mutations may result in more complex phenotype(s) not 
attributable to either of the two genes individually.  
 Another striking difference from SCA28 patients (Cagnoli et al., 2006; Di Bella et al., 
2010) was the clear evidence of systemic mitochondrial involvement in this patient. First, 
muscle biopsy revealed an isolated Complex I deficiency; second, patient’s cells presented an 
altered OPA1 pattern and mitochondrial network fragmentation (Fig. 4 and Supp. Fig. S8 and 
S9). Interestingly, syndromic and nonsyndromic Parkinson disease was recently observed in 
some patients carrying missense mutations in the OPA1 gene (Carelli et al., 2015; Lynch et 
al., 2017). OPA1 is a dynamin-like GTPase which regulates the critical balance between 
fusion and fission in the dynamic mitochondrial network (MacVicar & Langer, 2016). Fission 
(division of a single organelle into two or more independent structures) and the opposing 
reaction (fusion) are the main processes for adapting mitochondrial morphology to metabolic 
changes and cellular needs (Lee & Yoon, 2016). They are governed by dynamin-related 
protein-1 (DRP1) for fission, and mitofusins (MFN1 and MFN2) and OPA1 for fusion of the 
outer mitochondrial membrane and inner membrane, respectively. OPA1 exists in eight 
different forms generated by alternative splicing and protease cleavage, which are usually 
seen as five bands in gels: two long forms (L1 and L2) and three short forms (S1-3) (Ishihara 
et al., 2006). Since balance between long (profusion) and short (profission) forms is required 
for the maintenance of mitochondrial morphology and fitness, OPA1 processing involves 
several mitochondrial proteases and is differentially regulated under stress conditions (Song 
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et al., 2007; Ehses et al., 2009; MacVicar & Langer, 2016). Interestingly, in the patient’s 
cells, we observed a reduction of the long fusogenic OPA1 forms and an accumulation of the 
shortest ones that promote mitochondrial fission (Fig. 4B). Consistently, we observed 
fragmentation of the mitochondrial network which was present neither in SCA28 cells (Fig. 
4C-D and Supp. Fig. S9) nor in SPG7 (paraplegin-deficient) cells (Pfeffer et al., 2014). 
Richter and coll. (Richter et al., 2015) proposed that the loss of m-AAA may lead to 
overaccumulation of de novo mito-synthesysed proteins in the IMM which in turn would 
cause mitochondrial membrane potential dissipation and activation of the OMA1 
metalloprotease that processes the long OPA1 isoforms to the shortest ones. However, we 
could not detect any significant alteration of OMA1 mRNA in the patient’s cells (Supp. Fig. 
S10), which suggests that activation, if any, of OMA1 occurs at the protein level, as 
previously proposed (Head et al., 2009; Baker et al., 2014; Bohovych et al., 2014; Consolato 
et al., 2018). We can therefore hypothesize that the simultaneous occurrence of an AFG3L2 
dominant-negative mutation in the crucial ATP sensor and a halved dose of its companion 
paraplegin may alter both quantitatively and qualitatively the subunit composition and 
availability of m-AAA complexes to such extent as to severely impair mitochondria fitness 
with deficiency of respiratory chain Complex I and abnormal OPA1 processing by the stress-
activated OMA1 protease, detectable also in non-neuronal cell lines. Furthermore, since 
expression data indicate that the levels of each subunit of the m-AAA protease are very 
different in distinct subsets of neurons (Martinelli et al., 2009; Di Bella et al., 2010), it is 
conceivable that a combined defect of both subunits might cause neuronal dysfunction 
distinct from that occurring in AFG3L2-associated SCA28 or paraplegin-associated SPG7, 
thus accounting for the peculiar phenotype observed in the patient reported here.  
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In conclusion, this study suggests that co-occurring mutations in both components of 
the mitochondrial m-AAA proteases may cause a novel m-AAA-pathy with a crucial 
pathogenic role of OPA1. These results would also widen the repertoire of disease genes 
causing early-onset parkinsonism and strengthen the crucial role of mitochondrial 
dysfunction — and in particular of mitochondrial dynamics and protein quality control — in 
a growing spectrum of neurodegenerative phenotypes. However, further experiments aimed 
at rescueing the cell phenotype and/or evidence for further cases with a similar genotype will 
be required for confirming that concurrent alterations of both components of the m-AAA 
complex are responsible for such a distinct cellular and clinical phenotype. 
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Legends to figures 
 
Figure 1. Segregation of AFG3L2 and SPG7 mutations and SPECT/DaTscan  
(A) Pedigree of family MI-PPS0722. Square and circle symbols are male and female 
individuals, respectively. The symbol filled in black represents the affected individual. 
AFG3L2 and SPG7 genotypes are indicated under the symbols of the sampled individuals. 
Non-paternity for subject I-1 could be confidently excluded by segregation analyis using 
highly polymorphic VNTR markers (3'APOB-VNTR and D11S533). Low-level somatic 
mosaicism for AFG3L2
R468C
 was also excluded by deep sequencing for both I-1 and I-2 (see 
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Supp. Fig. S4). (B) Single photon emission computed tomography (SPECT) brain imaging 
with 
123
I-Ioflupane injection (DaTscan™) in the proband II-1. Semi-quantitative analysis 
showed bilateral depletion of striatal dopamine transporter. Striatum: 0.65 (R), 0.67 (L) (n.v., 
1.5-2.9); caudate: 0.75 (R), 0.78 (L) (n.v., 1.7-3.3); putamen: 0.52 (R), 0.56 (L) (n.v., 1.4-
3.1); putamen/caudate ratio: 0.70 (R), 0.71 (L) (n.v., ≥0.7). 
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Figure 2. Respiratory phenotype of yta10Δyta12Δ yeast cells expressing AFG3L2R468C 
 (A, B) Serial dilutions of normalized yeast cultures were spotted on YEP plates containing 
2% glucose (YPD) or 2% glycerol (YPG) and incubated at 28°C for 3 days. Respiratory 
competence was deduced by the ability to grow on 2% glycerol (YPG). (A) Respiratory 
phenotype of K699 (WT yeast strain) and yta10Δyta12Δ cells expressing either normal (WT) 
or mutant human AFG3L2 (p.R468C and the two reference mutations p.E691K and p.S674L 
previously described (Di Bella et al., 2010)). (B) Respiratory phenotype of K699 and 
yta10Δyta12Δ cells coexpressing either normal or mutant human AFG3L2 with human 
paraplegin. (C) Enzyme activity of respiratory chain complexes III, IV, and V in isolated 
mitochondria from yta10Δyta12Δ m-AAA-deficient yeast cells expressing normal or mutated 
AFG3L2 in the absence and in the presence of paraplegin. Ubiquinol c oxidoreductase 
(Complex III) specific activity is expressed as nanomoles of cytochrome c reduced per 
minute per milligram of protein. Cytochrome c oxidase (Complex IV) specific activity is 
expressed as nanomoles of cytochrome c
red
 oxidized per minute per milligram of protein. 
ATPase (Complex V) specific activity is expressed as nanomoles of NADH oxidized per 
minute per milligram of protein. Bars and vertical lines indicate mean and ±1SD of 3 
independent experiments, respectively. Values in parentheses indicate percentage of activity 
compared to that of AFG3L2
WT
. Asterisks indicate a statistically significant (*P ≤ 0.05; **P 
≤ 0.005) difference from AFG3L2WT, as determined by Student’s t-test. 
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Figure 3. Functional analysis of m-AAA in yeast 
(A, B) Proteolytic and dislocase (ATPase) activity of AFG3L2
R468C
 in yeast. (A) 
Fluorescence immunoblot analysis of MrpL32 precursor (p) and mature (m) form in yeast 
cells expressing either WT or mutant human AFG3L2 (left panel) and co-expressed with 
paraplegin (right panel). Proteolytic competence is measured as precursor accumulation 
expressed as the percent ratio of precursor level to total (p + m) level. MrpL32 levels were 
normalized to the loading control protein -actin. Histograph reports densitometric 
quantitation of precursor accumulation (indicated by p/(p + m) %) of 3 independent 
 Magri et al. -  
 
This article is protected by copyright. All rights reserved. 
 
35 
experiments. Asterisks indicate a statistically significant (*P ≤0.01; **P ≤0.001) difference 
from AFG3L2
WT
 (lane 2) as determined by Student’s t-test. (B) Fluorescence immunoblot 
analysis of Ccp1 precursor (p) and mature (m) forms in yeast cells expressing either WT or 
mutant human AFG3L2 (left panel) and coexpressed with paraplegin (right panel). The 
dislocase (ATPase) competence is measured as precursor accumulation expressed as the 
percent ratio of precursor level to total (p + m) level. Ccp1 levels were normalized to the 
loading control protein -actin. Each bar graph reports densitometric quantification of 
precursor accumulation (indicated by p/(p + m) %) of 3 independent experiments. Asterisks 
indicate a statistically significant (*P ≤0.05; **P ≤0.0005) difference from AFG3L2WT (lane 
2) as determined by Student’s t-test. Red bars: strain expressing AFG3L2R468C; blue bars: 
reference strains (yta10Δyta12Δ, AFG3L2WT and control mutants as in Fig. 2). Bars and 
vertical lines indicate mean and ±1SD, respectively. (C, D) m-AAA maturation impairment 
in yeast strain expressing AFG3L2
R468C
. (C) Immunoblot analysis of human AFG3L2 
autocatalytic processing in yeast strains. (D) Immunoblot analysis of human AFG3L2 
autocatalytic processing and paraplegin maturation in strains coexpressing paraplegin. m, 
mature; p, precursor; i, intermediate. Asterisks indicate paraplegin nonspecific degradation 
products. 
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Figure 4. OPA1 and mitochondrial network analysis in patient’s fibroblasts 
(A) Immunoblot and quantitative analysis of OPA1 in fibroblast extracts cultured in medium 
containing glucose or galactose, a mild metabolic stress inducer that enhances mitochondrial 
dysfunction (Palmfeldt et al., 2009). The alpha subunit of mitochondrial trifunctional protein 
(MTP) was used as a loading control. OPA1 long forms (L1 and L2) short forms (S1, S2 
and S3). C1 and C2, normal controls; P, patient. Histograph reports densitometric 
quantitation of OPA1 forms (expressed as OPA1 form/total OPA1 %) of 3 independent 
experiments.  Bars and vertical lines indicate means and ± 1 SD, respectively.  (B, C) 
Analysis of mitochondrial morphology in patient-derived fibroblasts. (B) Representative 
confocal images of mitochondria stained with Mitotracker Red. Control and patient 
fibroblasts cultured in glucose or galactose medium were stained with Mitotracker Red. Scale 
bars = 5 µm. (C) The graph shows average Aspect ratio (shape) and Formfactor (branching) 
values for mitochondria in the four conditions: patients or control cells cultured with or 
without galactose. Bars and vertical lines indicate means and ± 1 SD, respectively, of values 
obtained from the analysis of four randomly selected cells. Red bars = patient; Blue bars = 
control. Asterisks indicate a statistically significant (*P ≤ 0.005) difference from control as 
determined by Student’s t-test. C, control, P, patient. 
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